Related to this topic: Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Schilder's Disease

Synonyms: diffuse sclerosis, myelinoclastic diffuse sclerosis

Schilder's myelinoclastic diffuse sclerosis is a rare sporadic demyelinating disease that usually affects children between 5 and 14 years old. It was first described by Paul Schilder in 1912 as a severe and fulminating syndrome of acute demyelinating disease.1 There is widespread demyelination of both cerebral hemispheres with varying degrees of axonal injury.

The term diffuse cerebral sclerosis was originally used to identify a heterogeneous group of diseases affecting cerebral white matter. Most of the diseases previously classified as Schilder's disease are now classified as dysmyelinating leucodystrophies or are included within the spectrum of multiple sclerosis. Schilder's disease now appears to belong to a heterogenous group of disorders which includes Krabbe disease, sudanophilic cerebral sclerosis, metachromatic leukodystrophy and adrenoleukodystrophy.1 Cases initially reported as familial Schilder's disease are probably sudanophilic cerebral sclerosis, Krabbe disease or metachromatic leukoencephalopathy.2

The diagnostic criteria established by Poser in 1985:3

  • One or two roughly symmetrical large plaques. Plaques are greater than 2 cm diameter.
  • No other lesions are present and there are no abnormalities of the peripheral nervous system.
  • Results of adrenal function studies and serum very long chain fatty acids are normal.
  • Pathological analysis is consistent with subacute or chronic myelinoclastic diffuse sclerosis.
Epidemiology

Schilder's disease is very rare.

Presentation
  • The onset of illness is usually subacute, but may be more sudden.
  • It often occurs shortly after an infectious illness. May start with headache, malaise and fevers.
  • A wide variety of neurological abnormalities may occur, including aphasia, memory disturbances, irritability, confusion, disorientation, and behavioural disturbances. Patients may appear to be psychotic.
  • Deafness is common. Other brainstem or cerebellar deficits include vertigo, paralysis of eye movements, nystagmus, facial palsy, dysarthria or dysphagia. Peripheral cranial nerve abnormalities may occur, including optic neuritis and optic atrophy.
  • Cortical blindness is common. Hemiparesis or cortical sensory deficits may occur.
  • Malnutrition and cachexia are commonly reported in the later chronic stages of illness.
Differential Diagnosis
Investigations
  • Serum very long chain fatty acid studies and adrenal function studies must be normal, otherwise suggests the diagnosis as adrenoleukodystrophy.
  • EEG: abnormalities such as periodic lateralised epileptiform discharges suggest the alternative diagnosis of SSPE or progressive rubella panencephalitis.
  • Lumbar puncture:
    • CSF may be normal or may contain lymphocytes and monocytes.
    • Mild to moderate elevation of CSF protein is often found.
    • Elevation of CSF IgG is found in 50-60% of cases. CSF abnormalities on the CSF immune profile, such as oligoclonal bands or elevation of the CSF serum IgG index or CSF IgG synthetic rate further suggest subacute sclerosing panencephalitis (SSPE) or progressive rubella panencephalitis.
    • Ruling out an infectious aetiology is essential: includes viral cultures of CSF, nasal or oropharyngeal secretions, and rectal swab. Acute titres for e.g. Brucella, Bartonella, Ebstein-Barr virus, Cytomegalovirus, Mycoplasma, Herpes viruses and other infectious agents should be assayed.
  • MRI: demonstrates 1 or 2 large confluent lesions in the deep white matter, usually the centrum semiovale. Additional lesions in the brain or spinal cord may imply multiple sclerosis, acute disseminated encephalomyelitis or some other alternative diagnosis.
  • Sequential EEG studies: show progressive deterioration in background organization, with predominantly high-voltage irregular slowing. Periodic lateralising discharges or other pseudo-rhythmical high-voltage discharges suggest the diagnosis of SSPE.5
  • Brain biopsy specimens may be required to exclude infection, tumours, vasculitic or other inflammatory processes.
Management
  • Corticosteroids may be effective in some patients.6
  • There is no information regarding the efficacy of immunomodulatory therapy in Schilder's disease as defined by the strict criteria established by Poser.5
  • Management is mainly supportive, including physiotherapy, occupational therapy and nutritional support in the later stages.
Complications
  • Cerebral herniation
  • Development of pneumonia, sepsis, pulmonary embolisation, skin breakdown and ulceration in individuals who are immobile and bed-bound.
  • Complications due to corticosteroids
Prognosis
  • Only nine patients that fit the tightly defined diagnosis of diffuse sclerosis have been reported. In these patients, deterioration has been constant and usually rapid with death within five years.
  • In those categorised as having transitional sclerosis by Poser in 1957, the mean duration of survival was reported as 6.2 years after onset. Disease duration was less than 1 year in 40% of cases.3
  • Pre-pubertal cases, those with a good response to corticosteroids and those found to have smaller lesions may have a better prognosis.

Document References
  1. www.whonamedit.com; Schilder's Disease
  2. OMIM - Schilder's Disease; Schilder's Disease
  3. Poser CM, Goutieres F, Carpentier MA, et al; Schilder's myelinoclastic diffuse sclerosis. Pediatrics. 1986 Jan;77(1):107-12. [abstract]
  4. Kurul S, Cakmakci H, Dirik E, et al; Schilder's disease: case study with serial neuroimaging. J Child Neurol. 2003 Jan;18(1):58-61. [abstract]
  5. Rust RS; Diffuse Sclerosis. eMedicine; April 2006.
  6. Fernandez-Jaen A, Martinez-Bermejo A, Gutierrez-Molina M, et al; [Schilder's diffuse myelinoclastic sclerosis] Rev Neurol. 2001 Jul 1-15;33(1):16-21. [abstract]
Acknowledgements EMIS is grateful to Dr Colin Tidy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 2751
Document Version: 20
DocRef: bgp1789
Last Updated: 21 Mar 2007
Review Date: 20 Mar 2009








Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.

Want to advertise on this site? Find out how >>








Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.

Want to advertise on this site? Find out how >>


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page